Would you still obtain Ki-67 prior to use of adjuvant abemaciclib in a patient who has otherwise met MonarchE treatment criteria, such as 1-3 positive LNs, grade 3 and/or tumor >5 cm?   

Patient is pre-menopausal and has cT3cN1, grade 2, ER positive, Her 2 negative IDC. Metastatic disease to axillary LNs was biopsy-proven. Patient was given neoadjuvant ddAC-T with excellent response (ypT1cN0(i+)) post-lumpectomy.  Would their response to neoadjuvant chemotherapy affect your decision?

Answer from: Medical Oncologist at Academic Institution